Suppr超能文献

锂盐增效治疗抵抗性抑郁症的疗效预测因素。

Predictors of efficacy in lithium augmentation for treatment-resistant depression.

机构信息

Department of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.

出版信息

J Affect Disord. 2010 Sep;125(1-3):165-8. doi: 10.1016/j.jad.2009.12.025. Epub 2010 Jan 20.

Abstract

BACKGROUND

Lithium augmentation is widely applied for treatment-resistant depression, however, the clinical predictors of its efficacy regarding polarity and bipolarity are unknown.

METHODS

We retrospectively examined the predictive value of clinical variables in 79 depressed patients who underwent lithium augmentation after failure to respond to antidepressant monotherapy. Lithium augmentation efficacy was evaluated by Clinical Global Impression Improvement assessment 4 to 8 weeks after initiating lithium administration; subjects with scores of 1 and 2 were defined as responders, and those with scores of 3 to 7 as non-responders. Clinical variables, including demographic and diagnostic variables, psychiatric medication, and clinical variables, were compared between groups. The bipolarity of patients with major depressive disorder as a final diagnosis was evaluated in association with the lithium augmentation efficacy. Data were analyzed using a chi-square test or Fisher's test.

RESULTS

The lithium augmentation efficacy rate was 41% among 79 enrolled patients (14 dropped out, 32 responders, and 33 non-responders). Lithium augmentation was significantly more effective for patients with a final diagnosis of bipolar disorder than with major depressive disorder (p=0.03). Subjects with more than three major depressive episodes showed a significant response to lithium augmentation (p=0.004). The rate of a family history of major depressive disorder/bipolar disorder in a first-degree relative was significantly higher in responders (34%) than in non-responders (7%, p=0.01), consistent with the association between the efficacy of lithium augmentation and bipolarity in major depressive disorder (responders=27% vs. non-responders=3%, p=0.03).

LIMITATION

The study was retrospective and severity was not analyzed.

CONCLUSION

Bipolar disorder, frequency of major depressive episodes, and family history of major depressive disorder/bipolar disorder in a first-degree relative were detected as predictors of lithium augmentation efficacy. Among them, family history of major depressive disorder/bipolar disorder in a first-degree relative was the most reliable predictor of lithium augmentation efficacy for bipolar disorder and major depressive disorder.

摘要

背景

锂盐增效治疗被广泛应用于治疗抵抗性抑郁症,然而,其对于单相和双相抑郁的疗效的临床预测因子尚不清楚。

方法

我们回顾性地检查了 79 例抑郁患者的临床变量,这些患者在抗抑郁药单药治疗失败后接受了锂盐增效治疗。锂盐增效治疗的疗效通过治疗 4 至 8 周后开始的临床总体印象改善评估来评估;评分 1 和 2 的患者定义为有效,评分 3 至 7 的患者定义为无效。比较了两组之间的人口统计学和诊断变量、精神药物和临床变量等临床变量。评估了最终诊断为单相重性抑郁障碍患者的双相性与锂盐增效治疗的疗效之间的关系。采用卡方检验或 Fisher 检验对数据进行分析。

结果

在纳入的 79 例患者中(14 例退出,32 例有效,33 例无效),锂盐增效治疗的有效率为 41%。最终诊断为双相障碍的患者的锂盐增效治疗效果显著优于单相重性抑郁障碍患者(p=0.03)。有超过三次重性抑郁发作的患者对锂盐增效治疗有显著反应(p=0.004)。一级亲属中有重性抑郁障碍/双相障碍家族史的患者中,有效者(34%)显著高于无效者(7%,p=0.01),与锂盐增效治疗对单相重性抑郁障碍的疗效与双相性之间的关系一致(有效者=27%,无效者=3%,p=0.03)。

局限性

该研究为回顾性研究,未分析严重程度。

结论

双相障碍、重性抑郁发作频率以及一级亲属中有重性抑郁障碍/双相障碍家族史被检测为锂盐增效治疗疗效的预测因子。其中,一级亲属中有重性抑郁障碍/双相障碍家族史是预测锂盐增效治疗对双相障碍和单相重性抑郁障碍疗效的最可靠预测因子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验